A phase 1/2 dose escalation study of TRU-015 in subjects with relapsed or refractory B cell non-Hodgkin's lymphoma

Trial Profile

A phase 1/2 dose escalation study of TRU-015 in subjects with relapsed or refractory B cell non-Hodgkin's lymphoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs TRU 015 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 04 Apr 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 27 Dec 2007 Status changed from initiated to recruiting.
    • 03 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top